Real-world impact of AUD pharmacotherapy on healthcare utilization, cost, and cost-effectiveness in the United States
AUD pharmacotherapy is significantly associated with lower alcohol-associated healthcare utilization, particularly IP care, and medical charges in real-world settings, with the largest economic benefits observed in patients without advanced liver disease. These findings support broader implementation of pharmacologic treatment for AUD, including in patients with ALD, and underscore the importance of early intervention to maximize cost-effectiveness.
Authors
- Shihui Jiang
- Hanna Blaney (ORCID: https://orcid.org/0000-0003-4919-9519)
- Chi M. Nguyen (ORCID: https://orcid.org/0000-0002-1582-1253)
- Jing Su (ORCID: https://orcid.org/0000-0001-5389-734X)
- Yang Li (ORCID: https://orcid.org/0000-0001-7024-7103)
- Wanzhu Tu
- Yining Li
- Suthat Liangpunsakul
Institutions
- Regenstrief Institute (US)
- Virginia Commonwealth University (US)
- Richard L. Roudebush VA Medical Center (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Hepatology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1097/hep.0000000000001720
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00